Firefly Neuroscience, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Greg Lipschitz
- Full Time Employees
- 17
- Sector
- Technology
- Industry
- Software - Application
- Address
- 1100 Military Road Kenmore NY United States of America 14217
- IPO Date
- Nov 28, 2002
- CIK
- 0000803578
- Website
- fireflyneuro.com
- Similar Companies
- Business
- Firefly Neuroscience, Inc. develops and commercializes artificial intelligence-powered neuroscientific solutions aimed at improving brain health outcomes for patients with mental illnesses and neurological disorders. Its core product is the FDA-510(k) cleared Brain Network Analytics (BNA) platform, a software-as-a-medical-solution that leverages AI and machine learning to analyze electroencephalogram (EEG) data recorded during rest and cognitive activity. This platform provides clinicians with objective, comprehensive insights into brain function and cognition, facilitating diagnosis and treatment of conditions such as major depressive disorder, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. The company's offerings also include the proprietary CLEAR (CLeaning EEG ARtifacts) platform, which significantly enhances EEG data preprocessing speeds and quality. Firefly serves pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners worldwide, and operates primarily out of its headquarters in Kenmore, New York. Founded in 2006, Firefly integrates a proprietary database with over 180,000 EEG/ERP brain scans representing multiple cognitive disorders and healthy controls, supporting its development of biomarkers and companion diagnostics. In recent years, Firefly Neuroscience has significantly expanded its capabilities and market presence. The company completed a merger with WaveDancer, Inc. in 2024, which facilitated its Nasdaq listing under the ticker AIFF and financial capitalization to support commercialization. In 2025, Firefly acquired Evoke Neuroscience for $6 million, a strategic move that tripled its patent holdings to 27, doubled its proprietary brain scan database, and increased its commercial user base tenfold. This acquisition included extensive electrophysiology data, historic revenues, and aligned with the company's objective to advance EEG/ERP-based foundation models of the human brain. Firefly has also formed notable collaborations, including a commercial agreement with the Institute of Human Genetics at Heidelberg University Hospital for neuroscience research utilizing its FDA-cleared BNA platform and partnerships with neuroscience pharmaceutical companies on clinical trials. The firm is actively developing its commercial footprint and intellectual property portfolio while advancing its AI-driven brain health technologies with NVIDIA GPU-powered processing enhancements and ongoing contributions to neuropsychiatric drug development and diagnostics. Firefly Neuroscience operates within the medical technology and AI sectors focused on neurosciences, targeting both research and clinical applications globally. Its products and services enhance precision neuroscience by providing standardized, objective, and rapid assessments of brain health, directly supporting drug development pipelines and clinical decision-making. The company has invested approximately $60 million in developing its analytical platforms and intellectual property since inception, positioning itself as a leader in AI-based brain health technology solutions. This description reflects Firefly Neuroscience's latest strategic changes, product innovations, market positioning, and geographical and industry footprint as of late 2025.
Company News
Firefly Neuroscience (NASDAQ:AIFF) vs. Pro Medicus (OTCMKTS:PMCUF) Head-To-Head Analysis
Firefly Neuroscience (NASDAQ: AIFF) Reports 291% Increase in TMS Center Customer Brain Scan Volumes
Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides
Firefly's AI-Driven Evoke System Powers Discovery of Novel Electrophysiological Biomarker for PTSD
Short Interest in Firefly Neuroscience, Inc. (NASDAQ:AIFF) Declines By 14.6%
With Brain Scan Volume Momentum Accelerating, Firefly Makes History by Building the World's First Known 200,000+ Standardized EEG/ERP Depository
Firefly Confirms Public-Private Partnership with the Department of War
Firefly Announces Discovery of New Brain Wave Biomarkers For Differential Diagnosis of ADHD
What's Going On With Firefly Neuroscience Stock On Friday?
Firefly Neuroscience Skyrockets — Brain Scan Breakthrough Fuels Rally
Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
Head-To-Head Contrast: Firefly Neuroscience (NASDAQ:AIFF) & SmartRent (NYSE:SMRT)
Financial Review: Firefly Neuroscience (NASDAQ:AIFF) and Aurora Innovation (NASDAQ:AUR)
Firefly Neuroscience (NASDAQ:AIFF) Trading Down 1.8% – Here’s Why
Firefly Neuroscience (NASDAQ:AIFF) Stock Price Down 3.7% – Here’s What Happened
Analyzing Wearable Devices (NASDAQ:WLDS) & Firefly Neuroscience (NASDAQ:AIFF)
Firefly Neuroscience Reports Third Quarter 2025 Financial Results
Firefly Neuroscience, Inc. (NASDAQ:AIFF) Short Interest Update
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Firefly Neuroscience, Inc. (NASDAQ: AIFF)
Firefly Neuroscience Partners with HealingMaps to Offer Cognitive Electrophysiology Analytics to Over 2,500 Ketamine, Psilocybin, and TMS Clinics Across North America